TNF-α Induces CCL28-Mediated Recruitment of Th22 Cells in Hepatocellular Carcinoma

The liver is a resilient organ, but when it becomes the site of a specific type of cancer called hepatocellular carcinoma, the body's internal defense system often turns against itself. This disease does not grow in a vacuum; it thrives within a complex neighborhood of cells, chemicals, and signals known as the tumor microenvironment. In this crowded space, the immune system sends out specialized soldiers, including a type of white blood cell called a T cell, to fight the infection. However, some of these cells can be tricked into helping the tumor grow instead of destroying it. One such group is a subset of T cells known as Th22 cells. While these cells usually help repair damaged tissue, in the context of liver cancer, they seem to gather in large numbers around the tumor, potentially fueling its expansion. The central mystery for scientists has been understanding exactly how the cancer cells call these specific helpers to their location and what signals they use to keep them there.

A team of researchers from hospitals and universities in China set out to solve this puzzle by tracing the path of communication between liver cancer cells and these immune cells. They began by looking at the blood of patients who had just been diagnosed with this type of liver cancer and comparing it to the blood of healthy people. They found a clear difference: the patients had significantly fewer of the raw, untrained immune cells that the body uses to build new defenses, while they had a much higher number of the specific Th22 cells that were already active. At the same time, the patients' blood contained high levels of a chemical messenger called CCL28. This chemical acts like a beacon, designed to attract cells that have a specific receptor, or antenna, on their surface called CCR10. The researchers suspected that the cancer cells were using this beacon to pull the Th22 cells into the tumor.

To test this idea, the scientists worked with liver cancer cells and immune cells in the laboratory. They discovered that a common inflammatory signal, a protein called TNF-α, acts as the switch that turns on this entire process. When the researchers exposed healthy immune cells to this signal, the cells changed their identity, transforming from untrained cells into the specific Th22 type that the cancer seems to favor. Simultaneously, the cancer cells themselves responded to this same signal by producing more of the CCL28 beacon, while the immune cells responded by building more CCR10 antennas on their own surfaces. This created a perfect setup for recruitment: the cancer cells shouted for help with a chemical signal, and the immune cells, now primed to listen with increased receptors, moved toward the source.

The team then dug deeper to understand how the immune cells knew to build more of these antennas. They found that the inflammatory signal TNF-α activates a master control pathway inside the cell known as NF-κB. This pathway sends a specific piece of the control machinery, a protein called p65, into the cell's command center, the nucleus. Once inside, p65 attaches directly to the genetic instructions for the CCR10 antenna and tells the cell to start making more of them. The researchers confirmed this by showing that if they blocked p65 from entering the nucleus, the cells stopped making the extra antennas, even when the inflammatory signal was present. They also proved that the increase in antennas was not because the old ones were lasting longer, but because the cells were actively building new ones at a faster rate.

Finally, the researchers tested whether this chain of events actually caused the immune cells to move toward the cancer. They set up a migration experiment where immune cells were placed above a layer of liver cancer cells. In normal conditions, the immune cells moved down toward the cancer. However, when the researchers silenced the gene that produces the CCL28 beacon in the cancer cells, or when they blocked the CCR10 antenna on the immune cells, the movement stopped. The immune cells no longer felt the pull. This confirmed that the cancer cells recruit these specific Th22 cells by releasing the CCL28 chemical, which attracts the cells that have been programmed to listen for it.

The study reveals a continuous loop that helps the tumor grow. The cancer cells release inflammatory signals that create more Th22 cells and more beacons. These Th22 cells then gather at the tumor site and release their own inflammatory signals, which in turn tell the cancer cells to make even more beacons and antennas. This cycle creates a self-sustaining environment where the immune system is constantly recruited to support the tumor rather than fight it. By mapping out this specific pathway, the researchers have identified a new way the liver cancer communicates with the body's defenses. While the study was conducted in the laboratory and on blood samples, it suggests that interrupting this specific line of communication—perhaps by blocking the beacon or the antenna—could be a new strategy for treating the disease. The findings offer a clearer picture of how the tumor microenvironment is built and provide a potential target for future therapies aimed at stopping the cancer from calling its own reinforcements.